Acurx Pharmaceuticals Inc (NASDAQ: ACXP) kicked off on Monday, up 18.79% from the previous trading day, before settling in for the closing price of $0.43. Over the past 52 weeks, ACXP has traded in a range of $0.30-$3.33.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -7.84% over the past five years. While this was happening, its average annual earnings per share was recorded 42.53%. With a float of $20.39 million, this company’s outstanding shares have now reached $22.40 million.
Let’s look at the performance matrix of the company that is accounted for 4 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Acurx Pharmaceuticals Inc (ACXP) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Acurx Pharmaceuticals Inc is 13.17%, while institutional ownership is 14.90%. The most recent insider transaction that took place on Jan 06 ’25, was worth 25,000. In this transaction Director of this company bought 24,631 shares at a rate of $1.01, taking the stock ownership to the 27,708 shares. Before that another transaction happened on Jan 06 ’25, when Company’s Director bought 24,631 for $1.01, making the entire transaction worth $25,000. This insider now owns 137,183 shares in total.
Acurx Pharmaceuticals Inc (ACXP) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 42.53% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.59% during the next five years compared to -7.84% drop over the previous five years of trading.
Acurx Pharmaceuticals Inc (NASDAQ: ACXP) Trading Performance Indicators
Take a look at Acurx Pharmaceuticals Inc’s (ACXP) current performance indicators. Last quarter, stock had a quick ratio of 1.93.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.70, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.51 in one year’s time.
Technical Analysis of Acurx Pharmaceuticals Inc (ACXP)
Acurx Pharmaceuticals Inc (NASDAQ: ACXP) saw its 5-day average volume 1.46 million, a negative change from its year-to-date volume of 3.29 million. As of the previous 9 days, the stock’s Stochastic %D was 18.08%.
During the past 100 days, Acurx Pharmaceuticals Inc’s (ACXP) raw stochastic average was set at 28.11%, which indicates a significant increase from 28.11% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 453.82% in the past 14 days, which was higher than the 193.12% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.4157, while its 200-day Moving Average is $0.9460. Nevertheless, the first resistance level for the watch stands at $0.5625 in the near term. At $0.6142, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.6734. If the price goes on to break the first support level at $0.4516, it is likely to go to the next support level at $0.3924. The third support level lies at $0.3407 if the price breaches the second support level.
Acurx Pharmaceuticals Inc (NASDAQ: ACXP) Key Stats
The company with the Market Capitalisation of 12.00 million has total of 23,482K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -14,100 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -2,150 K.
